The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis

Cancer Immunology, Immunotherapy

Volumn 61, Issue 4, 2012, Pages 511-521

  Garrison, Kendra ^a   Hahn, Tobias ^a   Lee, Wen Cherng ^b   Ling, Leona E ^c   Weinberg, Andrew D ^a   Akporiaye, Emmanuel T ^a  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b Shanghai Medicilon Inc   (China)

^c BIOGEN   (United States)

Author keywords

4T1; Breast cancer; OX40; SM16; Small molecule kinase inhibitor; TGF ; TGF RI ALK5

Indexed keywords

ANTIMETASTATIC AGENT; OX40 ANTIBODY; PROTEIN KINASE INHIBITOR; SM 16; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SIZE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EFFECTOR CELL; FEMALE; LUNG METASTASIS; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZABICYCLO COMPOUNDS; CARCINOMA; DISEASE PROGRESSION; DRUG SYNERGISM; FEMALE; IMMUNOTHERAPY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; RECEPTORS, OX40; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR BURDEN;

EID: 84862492510     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1119-y     Document Type: Article

References (51)

1. Huddleston CA, Weinberg AD, Parker DC (2006) OX40 (CD134) engagement drives differentiation of CD4 + T cells to effector cells. Eur J Immunol 36(5):1093-1103. doi:10.1002/eji.200535637
2. Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U, Orfanos CE (1998) Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 77(9):1492-1494 (Pubitemid 28190751)
3. Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G, Rodeck U (1999) Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 155(2):537-547 (Pubitemid 29370403)
4. Shim KS, Kim KH, Han WS, Park EB (1999) Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection. Cancer 85(3):554-561 (Pubitemid 29075277)
5. Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL (1995) Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 222(2):155-162
6. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA (1992) Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 52(24):6949-6952 (Pubitemid 23006305)
7. Walker RA, Dearing SJ (1992) Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer 28(2-3):641-644
8. Hahn T, Polanczyk MJ, Borodovsky A, Ramanathapuram LV, Akporiaye ET, Ralph SJ (2011) Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors. Curr Pharma Biotechnol (in press)
9. Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ, Ramanathapuram LV, Arteaga CL, Akporiaye ET (2003) Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 63(8):1860-1864 (Pubitemid 36460849)
10. Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, Kohn E, Tang B, Sabzevari H, Anver MR, Lawrence S, Danielpour D, Lonning S, Berzofsky JA, Wakefield LM (2008) An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 68(10):3835-3843. doi:10.1158/0008-5472.CAN-08-0215
11. Sharma RK, Elpek KG, Yolcu ES, Schabowsky RH, Zhao H, Bandura-Morgan L, Shirwan H (2009) Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res 69(10):4319-4326. doi:10.1158/0008-5472.CAN-08- 3141
12. Futagawa T, Akiba H, Kodama T, Takeda K, Hosoda Y, Yagita H, Okumura K (2002) Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 14(3): 275-286 (Pubitemid 34213639)
13. Robertson SJ, Messer RJ, Carmody AB, Mittler RS, Burlak C, Hasenkrug KJ (2008) CD137 costimulation of CD8 + T cells confers resistance to suppression by virus-induced regulatory T cells. J Immunol 180(8):5267-5274
14. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL (2002) Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109(12):1551-1559 (Pubitemid 34663517)
15. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, Strome SE, Pease LR, Chen L (2002) Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 109(5):651-659. doi:10.1172/JCI14184 (Pubitemid 34204844)
16. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M (2004) SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64(21):7954-7961 (Pubitemid 39446929)
17. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6(4):443-446. doi:10.1038/74704 (Pubitemid 30208162)
18. Weiner LM, Adams GP (2000) New approaches to antibody therapy. Oncogene 19(53):6144-6151. doi:10.1038/sj.onc.1204000 (Pubitemid 32059465)
19. Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, Sun L, Shan F, Singh J, Lee WC, Albelda SM, Ling LE (2007) A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res 67(5):2351-2359 (Pubitemid 46424257)
20. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20(11):2624-2632 (Pubitemid 34575634)
21. Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, Heitjan DF, June C, Kaiser LR, Ling LE, Albelda SM (2008) Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res 14(12):3966-3974. doi:10.1158/1078-0432.CCR-08- 0356
22. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R (2003) Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 4(12):1191-1198. doi:10.1038/ni1009 (Pubitemid 37540688)
23. Rausch MP, Hahn T, Ramanathapuram L, Bradley-Dunlop D, Mahadevan D, Mercado-Pimentel ME, Runyan RB, Besselsen DG, Zhang X, Cheung HK, Lee WC, Ling LE, Akporiaye ET (2009) An orally active small molecule TGF-{beta} receptor I antagonist inhibits the growth of metastatic murine breast cancer. Anticancer Res 29(6):2099-2109
24. Baselga J, Albanell J, Molina MA, Arribas J (2001) Mechanism of action of trastuzumab and scientific update. Seminal Oncol 28(5 Suppl 16):4-11 (Pubitemid 33065104)
25. Gramaglia I, Weinberg AD, Lemon M, Croft M (1998) Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 161(12):6510-6517 (Pubitemid 28562188)
26. Fujita T, Ukyo N, Hori T, Uchiyama T (2006) Functional characterization of OX40 expressed on human CD8 + T cells. Immunol Lett 106(1):27-33. doi:10.1016/j.imlet.2006.04.001 (Pubitemid 44093048)
27. Toi M, Horiguchi K, Bando H, Saji S, Chow LW (2005) Trastuzumab: updates and future issues. Cancer Chemother Pharmacol 56 (Suppl 1):94-99. doi:10.1007/s00280-005-0110-8
28. Song J, Salek-Ardakani S, Rogers PR, Cheng M, Van Parijs L, Croft M (2004) The costimulation-regulated duration of PKB activation controls T cell longevity. Nat Immunol 5(2):150-158. doi:10.1038/ni1030ni1030 (Pubitemid 38208356)
29. Montemurro F, Valabrega G, Aglietta M (2004) Trastuzumab-based combination therapy for breast cancer. Expert Opin Pharmacother 5(1):81-96. doi:10.1517/14656566.5.1.81 (Pubitemid 38072721)
30. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M (2001) OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15(3):445-455 (Pubitemid 32907391)
31. Ioannou S, Voulgarelis M (2010) Toll-like receptors, tissue injury, and tumourigenesis. Mediators Inflamm. doi:10.1155/2010/581837
32. Takeda I, Ine S, Killeen N, Ndhlovu LC, Murata K, Satomi S, Sugamura K, Ishii N (2004) Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 172(6):3580-3589 (Pubitemid 38337939)
33. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, Colombo MP (2005) Triggering of OX40 (CD134) on CD4(+)CD25 + T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105(7):2845-2851. doi:10.1182/blood-2004-07-2959 (Pubitemid 40446278)
34. Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A, Killeen N, Ishii N, Chang Li X (2007) OX40 costimulation turns off Foxp3 + Tregs. Blood 110(7):2501-2510. doi:10.1182/blood-2007-01-070748 (Pubitemid 47523172)
35. Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD (2008) OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res 68(13):5206-5215
36. Morris A, Vetto JT, Ramstad T, Funatake CJ, Choolun E, Entwisle C, Weinberg AD (2001) Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo. Breast Cancer Res Treat 67(1):71-80 (Pubitemid 32703390)
37. Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, Vetto JT, Urba WJ, Alvord G, Bunce C, Shields J (2000) Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 164(4):2160-2169 (Pubitemid 30108775)
38. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S (2000) Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 60(19):5514-5521
39. Dexter DL, Kowalski HM, Blazar BA, Fligiel Z, Vogel R, Heppner GH (1978) Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res 38(10):3174-3181 (Pubitemid 9031291)
40. Zalckvar E, Yosef N, Reef S, Ber Y, Rubinstein AD, Mor I, Sharan R, Ruppin E, Kimchi A (2010) A systems level strategy for analyzing the cell death network: implication in exploring the apoptosis/autophagy connection. Cell Death Differ 17(8):1244-1253. doi:10.1038/cdd.2010.7
41. Wexler H (1966) Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst 36(4):641-645
42. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, Coutant F, Metivier D, Pichard E, Aucouturier P, Pierron G, Garrido C, Zitvogel L, Kroemer G (2005) Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202(12):1691-1701. doi:10.1084/jem.20050915 (Pubitemid 41815875)
43. Maccubbin DL, Cohen SA, Ehrke MJ (1990) Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions. Cancer Immunol Immunother 31(6):373-380 (Pubitemid 20242563)
44. Oft M, Heider KH, Beug H (1998) TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8(23):1243-1252 (Pubitemid 28540052)
45. Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A (2009) Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 16(7):966-975. doi:10.1038/cdd.2009.33
46. Eisenberg-Lerner A, Kimchi A (2009) The paradox of autophagy and its implication in cancer etiology and therapy. Apoptosis 14(4):376-391. doi:10.1007/s10495-008-0307-5
47. Gorelik L, Flavell RA (2000) Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12(2):171-181 (Pubitemid 30398631)
48. Gorelik L, Flavell RA (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 7(10):1118-1122
49. Taraban VY, Rowley TF, O'Brien L, Chan HT, Haswell LE, Green MH, Tutt AL, Glennie MJ, Al-Shamkhani A (2002) Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur J Immunol 32(12):3617-3627. doi:10.1002/1521-4141(200212)32:12〈3617:AID- IMMU3617〉3.0.CO;2-M (Pubitemid 36024398)
50. Croft M (2003) Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 3(8): 609-620
51. Piconese S, Valzasina B, Colombo MP (2008) OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 205(4):825-839. doi:10.1084/jem.20071341 (Pubitemid 351549881)